相关实验视频

Updated: Jul 8, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

TPD52L2作为清细胞脏细胞癌的潜在预后和免疫治疗生物标志物

Hongbo Wang¹, Zhendong Liu², Yuelin Du¹

¹Department of Urology Surgery, Lanzhou University Second Hospital, Lanzhou, China.

Frontiers in oncology

|December 11, 2023

概括

瘤蛋白D52-Like 2 (TPD52L2) 在清细胞细胞癌 (ccRCC) 中被上调,与预后不佳相关. 针对TPD52L2可能为ccRCC患者提供新的治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学遗传学是一个

背景情况:

瘤蛋白D52-Like 2 (TPD52L2) 与B细胞分化有关.
TPD52L2在清细胞细胞癌 (ccRCC) 发病过程中的特定作用在很大程度上是未知的.

研究的目的:

研究TPD52L2在ccRCC中的表达,预后价值和功能作用.
探索TPD52L2与ccRCC中的临床特征,预后和瘤免疫微环境的关联.

主要方法:

来自公共数据库和ccRCC组织样本的多omics数据的分析.
统计分析包括威尔科克森测试,奇平方,卡普兰-梅尔,ROC曲线,回归和元分析.
在体外实验中使用siRNA在ccRCC细胞中击倒TPD52L2.

主要成果:

在ccRCC中,TPD52L2在mRNA和蛋白质水平上显著上调.
提升的TPD52L2表达与预后不佳有关,并作为一个独立的预后因素.
TPD52L2通过多个信号通路影响ccRCC的进展,并与免疫细胞丰度和免疫检查点相关联.

结论:

TPD52L2是ccRCC中的一种新型瘤蛋白,具有上调和与不良结果相关.
在ccRCC中,TPD52L2代表了一个潜在的治疗标和免疫疗法疗效评估的生物标志物.

关键词:

TPD52 像2 像2 这样清细胞细胞癌是什么?恶性现象型的恶性现象型.预后预后预后瘤微环境是一个微环境.

更多相关视频

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.